Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational Accepts healthy volunteers

Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age

NCT01985997
Conditions
Observation Safety
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
Not listed
Enrollment
95,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Oakland, California
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 12 more
Conditions
Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
Interventions
Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants, No treatment
Drug · Other
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
Female only
Enrollment
1,731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
2
States / cities
Morrisville, North Carolina • Wilmington, North Carolina
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, nsNSAIDs
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 23 more
Conditions
Haemophilia A
Interventions
Not listed
Lead sponsor
Octapharma
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Miami, Florida • New Orleans, Louisiana • St Louis, Missouri + 2 more
Conditions
Prostate Cancer, Hypogonadism, Male
Interventions
Testosterone cypionate
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Miami, Florida
Active, not recruiting No phase listed Observational

Geko™ Cross Therapy Registry - Wound

NCT05007301
Conditions
Wound, Venous Leg Ulcer, Diabetic Foot Ulcer, Arterial Leg Ulcer
Interventions
geko device
Device
Lead sponsor
Firstkind Ltd
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Fabry Disease, Pregnancy, Pregnancy Complications
Interventions
Not applicable- observational study
Other
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
135,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Active, not recruiting No phase listed Observational

Spinraza in Adult Spinal Muscular Atrophy

NCT03709784
Conditions
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type 3
Interventions
Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care, One time survey
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 7 more
Conditions
Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
Interventions
Cerene
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • Cincinnati, Ohio
Conditions
Blood and Lymphatic Diseases
Interventions
BIVV003, ST-400
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
7
States / cities
Oakland, California • Sacramento, California • Atlanta, Georgia + 3 more
Conditions
Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Interventions
Ultomiris
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting No phase listed Observational

Long-Term Follow-up Protocol

NCT04917887
Conditions
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida
Conditions
Asthma
Interventions
Xolair®
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Morrisville, North Carolina
Conditions
Paroxysmal Nocturnal Hemoglobinuria, PNH
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Adult Growth Hormone Deficiency
Interventions
Somapacitan
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Conditions
Human Immunodeficiency Virus
Interventions
Maraviroc along with an optimized background antiretroviral drug regimen, Optimized background antiretroviral drug regimen without maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
145
States / cities
Hobson City, Alabama • Huntsville, Alabama • Bakersfield, California + 87 more
Completed Phase 2 Interventional Results available

Asacol Acute Diverticulitis(DIVA)Study

NCT00554099
Conditions
Diverticulitis
Interventions
Mesalamine, Probiotic, Placebo, Dietary Advice, Antibiotic for Diverticulitis
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years to 85 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Merced, California + 33 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

An Observational Study of the T3 Pro Dental Implant System

NCT05498662
Conditions
Tooth Loss
Interventions
T3 Pro dental implant system
Device
Lead sponsor
ZimVie
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
New Orleans, Louisiana • Minneapolis, Minnesota
Conditions
Corneal Ectasia
Interventions
Corneal Collagen Cross-linking
Combination Product
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
11
States / cities
Palo Alto, California • Bloomington, Minnesota • Bozeman, Montana + 8 more
Not listed No phase listed Observational

Naloxegol US PMR CV Safety.

NCT02813356
Conditions
Opioid Induced Constipation
Interventions
naloxegol, non-PAMORA
Drug
Lead sponsor
Valinor Pharma LLC
Industry
Eligibility
Not listed
Enrollment
8,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Wilmington, Delaware • Hines, Illinois
Conditions
Stress Urinary Incontinence
Interventions
Macroplastique
Device
Lead sponsor
Uroplasty, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
19
States / cities
Tucson, Arizona • Irvine, California • Orange, California + 15 more
Conditions
Patients With Intraosseous Vascular Access Requiring Computed Tomography (CT) Exam
Interventions
Intraosseous delivery of CT contrast dye
Procedure
Lead sponsor
Vidacare Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Phoenix, Arizona • Sylmar, California • Gainesville, Florida + 1 more